Full Text View
Tabular View
Contacts and Locations
No Study Results Posted
Related Studies
Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.
This study is currently recruiting participants.
Verified by Erasmus Medical Center, March 2007
Sponsors and Collaborators: Erasmus Medical Center
Nierstichting Nederland (Dutch Kidney Foundation)
Pfizer
Information provided by: Erasmus Medical Center
ClinicalTrials.gov Identifier: NCT00407784
  Purpose

This study aims to evaluate the diagnostic value of the Aldosterone-Renin Ratio (ARR)as a screening test for primary aldosteronism among hypertensives. The test characteristics will be studied. Furthermore, the effect of eplerenone, a selective aldosterone-receptor antagonist will be studied.


Condition Intervention
Hyperaldosteronism
Hypertension
Drug: eplerenone

MedlinePlus related topics: High Blood Pressure
Drug Information available for: Aldosterone
U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Longitudinal, Defined Population, Prospective Study
Official Title: Aldosterone-Renin Ratio to Diagnose Primary Aldosteronism in a Population of Patients With Therapy-Resistant Hypertension: Test Characteristics, Diagnostic Value and Predictive Value for Antihypertensive Treatment. The Dutch ARRAT Study.

Further study details as provided by Erasmus Medical Center:

Estimated Enrollment: 500
Study Start Date: January 2007
Estimated Study Completion Date: November 2009
Detailed Description:

Although primary aldosteronism (PA) was formerly seen as a rare cause of hypertension, this condition is now thought to be the commonest cause of secondary hypertension, with the prevalence ranging up to 10-15 % of all hypertensives. Identification of patients with PA allows for specific treatment, for instance unilateral adrenalectomy in case of an aldosterone-producing adenoma or the administration of an aldosterone-receptor antagonist in case of bilateral adrenal hyperplasia.

Since the introduction of the aldosterone-renin ratio (ARR) as a screening tool for PA in 1981, there has been considerable debate about the diagnostic value. The values for aldosterone and renin are highly dependent on many factors, including posture, time of day and medication. Also, the cut-off values for the identification of PA remain controversial.

This study aims to evaluate the test characteristics of the ARR in a population of patients with therapy-resistant hypertension, the dependence of the ARR on medication type and the predictive value on the response on eplerenone, a selective aldosterone-receptor antagonist.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 18-65 years
  • blood pressure above 140 mmHg systolic and above 90 mmHg diastolic
  • use of at least 2 antihypertensive drugs

Exclusion Criteria:

  • known cause of hypertension, including white-coat hypertension
  • severe renal failure (kreat > 200 umol/l)
  • BMI above 32 kg/m2
  • poorly regulated diabetes mellitus (HbA1C > 8.0 %)
  • heart failure
  • stroke or myocardial infarction within 6 months before inclusion
  • angina pectoris
  • pregnancy
  • neoplastic disease, within 5 years before inclusion
  • alcohol abuse
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00407784

Contacts
Contact: Pieter Jansen, MD +31(0)-4632196 p.jansen.1@erasmusmc.nl
Contact: A.H. van den Meiracker, MD, PhD +31(0)-4634220 a.vandenmeiracker@erasmusmc.nl

Locations
Netherlands
Erasmus Medical Center Recruiting
Rotterdam, Netherlands
MCRZ, lokation Zuider/Clara Not yet recruiting
Rotterdam, Netherlands
Beatrix Hospital Not yet recruiting
Gorinchem, Netherlands
Sint Franciscus Gasthuis Not yet recruiting
Rotterdam, Netherlands
Ikazia Hospital Recruiting
Rotterdam, Netherlands
University Medical Center St. Radboud Not yet recruiting
Nijmegen, Netherlands
Oogziekenhuis Not yet recruiting
Rotterdam, Netherlands
Ruwaard van Putten Hospital Not yet recruiting
Spijkenisse, Netherlands
Vlietland Hospital Not yet recruiting
Schiedam, Netherlands
Academical Medical Center Not yet recruiting
Amsterdam, Netherlands
VU medical Center Not yet recruiting
Amsterdam, Netherlands
Twee Steden Ziekenhuis Not yet recruiting
Waalwijk, Netherlands
IJsselland Hospital Not yet recruiting
Capelle aan de IJssel, Netherlands
Sponsors and Collaborators
Erasmus Medical Center
Nierstichting Nederland (Dutch Kidney Foundation)
Pfizer
Investigators
Principal Investigator: A.H. van den Meiracker, MD, PhD Erasmus Medical Center
  More Information

Publications:
Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981 Nov;141(12):1589-93.
Gordon RD, Klemm SA, Stowasser M, Tunny TJ, Storie WJ, Rutherford JC. How common is primary aldosteronism? Is it the most frequent cause of curable hypertension? J Hypertens Suppl. 1993 Dec;11(5):S310-1. No abstract available.
Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003 May;17(5):349-52.
Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003 Nov;21(11):2149-57.
Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005 Feb;51(2):386-94.
Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens. 2006 Apr;24(4):737-45.
Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004 May;22(5):863-9. Review.

Study ID Numbers: MEC-2006-103, C05.2151, EudraCT nr: 2006-006618-13
Study First Received: December 4, 2006
Last Updated: March 6, 2007
ClinicalTrials.gov Identifier: NCT00407784  
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Erasmus Medical Center:
primary aldosteronism
hypertension
aldosteron-renin ratio
eplerenone
aldosteron-receptor antagonist
screening

Study placed in the following topic categories:
Eplerenone
Vascular Diseases
Endocrine System Diseases
Adrenal Gland Diseases
Endocrinopathy
Conn's syndrome
Adrenocortical Hyperfunction
Hyperaldosteronism
Primary aldosteronism
Hypertension

Additional relevant MeSH terms:
Aldosterone Antagonists
Hormone Antagonists
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Cardiovascular Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 11, 2009